Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results

Preclinical data suggest that inhibition of the metabotropic glutamate receptor 5 (mGluR5) receptor might hold therapeutic benefits in Fragile X syndrome (FXS). Treatment of Fmr1 knockout mice with mGluR5-negative allosteric modulators (NAMs) has been reported to correct a broad range of phenotypes...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuropsychopharmacology (New York, N.Y.) N.Y.), 2018-02, Vol.43 (3), p.503-512
Hauptverfasser:	Youssef, Eriene A, Berry-Kravis, Elizabeth, Czech, Christian, Hagerman, Randi J, Hessl, David, Wong, Chin Y, Rabbia, Michael, Deptula, Dennis, John, Amy, Kinch, Russell, Drewitt, Philip, Lindemann, Lothar, Marcinowski, Moritz, Langland, Rachel, Horn, Carsten, Fontoura, Paulo, Santarelli, Luca, Quiroz, Jorge A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescents Allosteric properties Anxiety Behavior Clinical trials Double-blind studies Drug dosages Females FMR1 protein Fragile X syndrome Glutamic acid receptors (metabotropic) Hallucinations Intellectual disabilities Mental disorders Mood Mutation Neurosciences Original Pediatrics Pharmaceuticals Product development Proteins Psychosis Randomization Teenagers Trends
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!